149 results on '"Zuily, Stephane"'
Search Results
2. Manual versus automatic chest compression devices for cardiopulmonary resuscitation under zero gravity (The MACCC - 0G STUDY)
3. Venous recanalisation in the setting of post-thrombotic syndrome: An expert consensus from the French Society of Vascular Medicine (SFMV) and the French Society of Cardiovascular Imaging and Interventional Radiology (SFICV)
4. Impact of thrombophilia on venous thromboembolism management
5. Toward harmonized interpretation of anticardiolipin and anti–β2-glycoprotein I antibody detection for diagnosis of antiphospholipid syndrome using defined level intervals and likelihood ratios: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
6. A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation
7. Thrombocytopenia in antiphospholipid syndrome: Is anticoagulation and/or antiaggregation always required?
8. Added value of antiphosphatidylserine/prothrombin antibodies in the workup of obstetric antiphospholipid syndrome: communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
9. Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial
10. Associations Among Antiphospholipid Antibody Types, Isotypes, and Titers: An AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Study
11. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis
12. Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
13. Semiquantitative interpretation of anticardiolipin and antiβ2glycoprotein I antibodies measured with various analytical platforms: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies
14. Reply
15. Thromboprophylaxis strategies to improve the prognosis of COVID-19
16. Anticoagulant interventions in hospitalized patients with COVID‐19: A scoping review of randomized controlled trials and call for international collaboration
17. Detection of anti‐domain I antibodies by chemiluminescence enables the identification of high‐risk antiphospholipid syndrome patients: A multicenter multiplatform study
18. Cardiovascular and connective tissue disorder features in FLNA-related PVNH patients: progress towards a refined delineation of this syndrome
19. Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders?
20. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria
21. Response to: Correspondence on ‘ACR/EULAR antiphospholipid syndrome classification criteria’ by Damoiseaux and van Beers
22. Response to: Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’ by Tanget al
23. Response to: Correspondence on ‘2023 ACR/EULAR antiphospholipid syndrome classification criteria’ by Miro-Muret al
24. 15th International Congress on Antiphospholipid Antibodies Task Force on Antiphospholipid Syndrome Classification Report
25. Clinical and Prognostic Significance of Non-criteria Antiphospholipid Antibody Tests
26. Disease and Risk Measurement Criteria in Antiphospholipid Syndrome
27. Definition and Epidemiology of Antiphospholipid Syndrome
28. 2023 ACR/EULAR antiphospholipid syndrome classification criteria
29. Thrombocytopenia in antiphospholipid syndrome: Is anticoagulation and/or antiaggregation always required?
30. Efforts to Better Characterize “Antiphospholipid Antibody Nephropathy” for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report
31. Efforts to Better Characterize "Antiphospholipid Antibody Nephropathy" for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report.
32. Review article: Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs
33. Efforts to Better Characterize 'Antiphospholipid Antibody Nephropathy' for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria: Renal Pathology Subcommittee Report
34. The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria.
35. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease
36. Le syndrome des antiphospholipides en néphrologie. Atteinte rénale et aspects pratiques de la prise en charge
37. Neural Network Diagnoses the Antiphospholipid Syndrome without Interrupting Anticoagulant Therapy
38. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study
39. Influence of Age and Renal Function on High-Sensitivity Cardiac Troponin T Diagnostic Accuracy for the Diagnosis of Acute Myocardial Infarction
40. Combination of copeptin and high-sensitivity cardiac troponin T assay in unstable angina and non-ST-segment elevation myocardial infarction: A pilot study
41. Impact of heart failure management unit on heart failure-related readmission rate and mortality
42. A new pro-thrombotic mechanism of neutrophil extracellular traps in antiphospholipid syndrome: impact on activated protein C resistance
43. Implication of folate deficiency in CYP2U1 loss of function
44. Risk of thrombosis, pregnancy morbidity or death in antiphospholipid antibodies positive patients with or without thrombocytopenia
45. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease
46. Additional file 5 of Cardiovascular and connective tissue disorder features in FLNA-related PVNH patients: progress towards a refined delineation of this syndrome
47. COVID-19 and antiphospholipid antibodies: A position statement and management guidance from AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION)
48. Implication of folate deficiency in CYP2U1 loss of function
49. Response to: Correspondence on 'ACR/EULAR antiphospholipid syndrome classification criteria' by Damoiseaux and van Beers.
50. Response to: Correspondence on '2023 ACR/ EULAR antiphospholipid syndrome classification criteria' by Tang et al.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.